The Food and Drug Administration (FDA) announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults. The agencys tentative approval means that although existing patents and/or exclusivity prevent U.S. marketing of Aspens product, it meets FDAs quality, safety and efficacy standards for U.S. marketing. This action makes this product available for potential procurement by President Bushs Emergency Plan for AIDS Relief.
This action is the first tentative approval of an HIV drug regimen manufactured by a non-U.S.-based generic pharmaceutical company. Once Aspen s marketing application was complete on January 13, 2005, FDA completed its review within two weeks.
Todays action honors the commitment of the Department of Health and Human Services and Secretary Thompson to the Presidents Emergency Plan for AIDS Relief, said Dr. Lester M. Crawford, acting FDA commissioner. The goal of the emergency plan is to make safe, effective and affordable quality drugs available quickly for patients with HIV/AIDS.
Through an expedited review process, FDA has worked diligently to approve a product with great public health significance. Our contributions to the goals of the emergency plan are an integral part of that effort, added Crawford.
The Emergency Plan for AIDS Relief, which President Bush first announced in his 2003 State of the Union Address, is currently providing $15 billion to fight the HIV/AIDS pandemic over five years, with a special focus on 15 of the hardest hit countries. It targets three specific areas related to HIV/AIDS:
- Prevention of HIV transmission
- Treatment of AIDS and associated conditions
- Care, including palliative care for HIV infected-individuals, and care for orphans and vulnerable children.
The tentatively approved regimen consists of co-packaged lamivudine/zidovudine fixed dose combination tablets and nevirapine tablets. Lamivudine/zidovudine fixed dose combination tablets are a version of the already approved Combivir tablets manufactured by GlaxoSmithKline, and nevirapine tablets are a version of Viramune tablets manufactured by Boehringer-Ingelheim. The new co-packaged product consists of two tablets (lamivudine/zidovudine and nevirapine) each to be taken twice daily, after the initial two-week initiation phase of this nevirapine regimen.
Source: FDA
Weekly Rounds: Four Years of COVID-19, AORN 2024 Conference Coverage, and More
March 18th 2024Here are 5 highlights from Infection Control Today®'s (ICT®’s) wide-ranging coverage of the infection prevention and control world. Everything from interviews with known opinion leaders to the news that infection preventionists and other health care professionals can use on their jobs.
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
Could Empathy Help Overcome Vaccine Hesitancy?
March 14th 2024Research findings reveal that correcting misinformation about vaccination can remarkably transform individuals' attitudes toward it. This highlights the crucial role of accurate information in making informed decisions about vaccination.
Empowering Safety: A Massachusetts General Hospital Team Is Pushing for Smoke-Free ORs
March 13th 2024At the AORN’s International Surgical Conference & Expo 2024, a team from Massachusetts General Hospital (MGH) showcased their transformative project, "Becoming Smoke-Free in the OR." This initiative underscored the critical need for smoke evacuation in surgical settings.
Hand Hygiene Practices in the Operating Room: A Collaborative Endeavor
March 13th 2024As explained on a poster at AORN 2024, perioperative nurses and infection preventionists unite in a proactive campaign to elevate hand hygiene within the operating room, resulting in improved adherence, decreased infections, and fortified patient outcomes.